Table 1 |
|
|
Vaccination and Immune Protection: HLA-DQ8/human CD4 Transgenic Mice |
|
|
Vaccination1 |
Challenge Survival2 |
|
|
|
|
SpeA (L42R) |
100% |
|
SpeA (L42R)-SpeB (C47S) |
100% |
|
Adjuvant only |
0% |
|
|
|
|
1Vaccinations at 0, 2 and 4 weeks (3 doses) with 10 μg of SpeA (L42R) or SpeA (L42R)-SpeB (C47S) in adjuvant or adjuvant only. 2Percent mice surviving wild-type SpeA challenge, 5 LD50 per mouse 2 weeks after last vaccination. 5 mice per group SpeA (L42R) and adjuvant only control; 4 mice for SpeA (L42R)-SpeB (C47S) vaccination. Experiments were performed twice with identical results. |
|
|
Ulrich Journal of Immune Based Therapies and Vaccines 2008 6:8 doi:10.1186/1476-8518-6-8 |
|
